Brief: Travere Therapeutics Q2 EPS USD -0.37
04/08/2026 21:02
BRIEF-Travere Therapeutics Q2 EPS USD -0.37 Aug 04 (Reuters) - Travere Therapeutics Q2 operating expenses USD 165.63 million.
- Q2 net income USD -34.797 million
- Q2 product sales USD 161.352 million
- Q2 operating income USD 3.954 million
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule